Serum, Plasma, and Urine Specimens
Serum, Plasma, and Urine Specimen Repository
Serum, plasma, and urine specimens are obtained from NHANES study participants aged six years and older who have given consent for their specimens to be used in future studies. Serum specimens are currently available from NHANES III (1988-1994); and serum, urine, and a limited number of plasma specimens are available from continuous NHANES (1999-present). Specimens from participants aged 1-5 years are limited but may be available in some years from 1999-present. In total, there are over 1 million combined serum, plasma, and urine specimens available. For more information on recent availability of biospecimens by age and survey years, please see the tables below.
- 1999-2020 Surplus Specimens Available [PDF – 148 KB]
- 1999-2020 Pristine Specimens Available [PDF – 201 KB]
- Pristine and Surplus Specimen NHANES III Table [PDF – 74 KB]
Proposal Guidelines
- Results of studies using stored biospecimens are not reported back to the participant. Therefore, all proposals seeking the use of NHANES serum, plasma, or urine for must not produce laboratory results that are clinically significant to the NHANES participant. Clinical significance is defined as:
- The test is performed by a CLIA-certified laboratory deeming the findings valid,
- The findings may have significant implications for the subjects’ health concerns, and
- A course of action is readily available to ameliorate or treat the concerns.
- All proposals will be evaluated by the NHANES Project Officer and a technical panel for scientific merit and lack of clinical significance to the NHANES participant. The proposal is then reviewed by the NCHS Human Subjects Contact, Confidentiality Officer, and Ethics Review Board (ERB) for any potential human subjects or confidentiality concerns.
Please see the Federal Registerexternal icon for more details on the proposal requirements and for evaluation criteria. For more information on the current availability of biospecimens or questions about the proposal requirements, please contact the NHANES Biospecimen Program.
Please use the proposal template [PDF – 118 KB] to write your proposal.
Submit all proposals via email to NHANES Biospecimen Program
Frequently Asked Questions
How long is the evaluation process?
The entire review process can range from 2-6 months.
What happens after my proposal is approved?
The NHANES Project Officer will contact you to arrange the transfer of biospecimens after an agreement has been signed (i.e., Inter-Agency Agreement or a Materials Transfer Agreement-Memorandum of Understanding). An interagency agreement will be developed to transfer funds for federal agencies or an invoice will be sent for the cost of the biospecimens for non-federal institutions.
What kind of studies can I do with the NHANES biospecimens?
NHANES is a nationally representative survey and biospecimens are best utilized to determine the prevalence of laboratory analytes of public health concern using the survey sample weights. Case-control studies are discouraged.
Can specimens be used for public health emergencies?
Yes, please e-mail the NHANES Biospecimen Program early in your proposal process to see if the program fits your study’s needs.
How much does it cost to use stored biospecimens?
The current cost is $15.00 per vial. Updates to the cost structure are posted in the Federal Register Notice.
Is there a time limit on how long I can use the serum, plasma, and urine specimens?
You must submit a progress report annually and if work continues beyond five years a new protocol may need to be submitted. Projects are expected to show progress. Projects not showing progress for two years or more may be asked to provide a justification for delay or return or dispose of specimens, as directed by NHANES.
Data Documentation Files using Serum, Plasma, and Urine Specimens
Autoantibodies – Anti-DFS70 Autoantibody Analyses
Released: July, 2022
Autoantibodies – Immunofluorescence Analyses
Released: August, 2019
IgG Antibody to Hepatitis E Virus and anti-HEV Western Blot
Released: September, 2016
Food Specific IgE(s) Sera
Released: May, 2015
Monoclonal Gammopathy of Undetermined Significance
Released: January, 2015
IgG and IgM Antibody to Hepatitis E Virus
Released: April, 2013
Monoclonal gammopathy of undetermined significance (MGUS)
Released: August, 2012
Partial Hepatitis C Virus RNA Sequences Isolated from Individuals
Released: August, 2012
ß-trace Protein ß2 Microglobulin
Released: April, 2012
Cystatin C, ß-trace Protein ß2 Microglobulin
Released: April, 2012
Inhibin B, Leuteinizing Hormone and Testosterone
Released: June, 2009
Dialkylphosphates
Released: May, 2009
Antibody to Hepatitis E Virus IgG
Released: August, 2008
Antibody to Periodontal Pathogens
Released: August, 2008
Antibody to MUMPs
Released: April, 2008
Cystatin C
Released: May, 2007
Antibody to Toxocara Larva Migrans
Released: January, 2007
Racial/Ethnic Variation in Sex Steroid Hormone Concentrations Across Age in US Men
Released: October, 2006
Insulin Like Growth Factor (IGF-I) and IGF Binding Protein-3
Released: September, 2006
Antibody to GAD65
Released: September, 2006
Antibody to Human Herpes Virus 8
Released: May, 2006
Optical Density to Cytomegalovirus
Released: May, 2006
Antibody to Cytomegalovirus IgG and IgM
Released: December, 2005
Pertussis Sera
Released: July, 2005
High-sensitivity cardiac troponins
Released: September, 2022
Autoantibodies – Anti-DFS70 Autoantibody Analyses
Released: July, 2022
N-terminal Pro-BNP
Released: July, 2022
Glycated albumin, Beta-2 Microglobulin, Cystatin C
Released: June, 2021
Autoantibodies – Immunofluorescence Analyses
Released: August, 2019
Norovirus Antibody
Released: July, 2017
Cytomegalovirus genotypes
Released: June, 2017
Urinary cytomegalovirus shedding
Released: January, 2016
Anti-Mullerian Hormone (AMH) & Inhibin-B
Released: January, 2015
Telomere Mean and Standard Deviation
Released: November, 2014
Aflatoxin B1-lysine – Serum
Released: August, 2012
Monoclonal gammopathy of undetermined significance (MGUS)
Released: August, 2012
Autoantibodies – Immunofluorescence & Immunoprecipitation Analyses
Released: June, 2011
Sex Steroid Hormone – Men
Released: May, 2010
Folic Acid – Unmetabolized
Released: October, 2009
Varicella-Zoster Virus Antibody
Released: March, 2009
Transferrin Receptor – Pregnant Women
Released: July, 2008
Cystatin C
Released: June, 2008
Mumps Antibody – Serum
Released: April, 2008
Cytomegalovirus IgG Antibodies – Serum
Released: March, 2008
Herpes Simplex Virus Type-1
Released: October, 2006
Perfluoroalkyl Chemicals – Serum
Released: October, 2006
High-sensitivity cardiac troponins
Released: September, 2022
Cancer antigen CA125, CA15.3 and HE4 IgG antibodies
Released: August, 2022
Autoantibodies – Anti-DFS70 Autoantibody Analyses
Released: July, 2022
N-terminal Pro-BNP
Released: July, 2022
Glycated albumin, Beta-2 Microglobulin, Cystatin C
Released: June, 2021
Human epididymal secretory protein E4 (HE4) – Serum (HE4)
Released: May, 2020
Autoantibodies – Immunofluorescence Analyses
Released: August, 2019
Cancer antigen CA125 and CA15.3 – Serum
Released: June, 2019
Cytomegalovirus Genotypes – Urine (Surplus)
Released: June, 2017
Urinary cytomegalovirus shedding
Released: January, 2016
Anti-Mullerian Hormone (AMH) & Inhibin-B
Released: January, 2015
Telomere Mean and Standard Deviation
Released: November, 2014
Limited Access Data: Folate – Folic acid & 5-methyltetrahydrofolate – Serum
Released: July, 2014
Brominated Flame Retardants (BFRs) – Pooled Samples
Released: July, 2013
Non-dioxin-like Polychlorinated Biphenyls – Pooled Samples Sera
Released: July, 2013
Pesticides-Organochlorine Metabolites
Released: July, 2013
Monoclonal gammopathy of undetermined significance (MGUS)
Released: August, 2012
Autoantibodies – Immunofluorescence & Immunoprecipitation Analyses
Released: June, 2011
Sex Steroid Hormone – Men
Released: May, 2010
Thyroid Profile
Released: February, 2010
Limited Access Data: Folic Acid – Unmetabolized
Released: October, 2009
Varicella-Zoster Virus Antibody
Released: March, 2009
Polyfluoroalkyl Chemicals – Pooled Samples (Surplus)
Released: October, 2008
Transferrin Receptor – Pregnant Women
Released: July, 2008
Cystatin C
Released: June, 2008
Mumps Antibody – Serum
Released: April, 2008
Cytomegalovirus IgG Antibodies – Serum
Released: March, 2008
Herpes Simplex Virus Type-1
Released: October, 2006
Perchlorate, Nitrate & Thiocyanate – Urine
Released: September, 2006
High-sensitivity cardiac troponins
Released: September, 2022
Autoantibodies – Anti-DFS70 Autoantibody Analyses
Released: July, 2022
N-terminal Pro-BNP
Released: July, 2022
Glycated albumin, Beta-2 Microglobulin, Cystatin C
Released: June, 2021
Autoantibodies – Immunofluorescence Analyses
Released: August, 2019
Norovirus Antibody
Released: July, 2017
Cytomegalovirus genotypes
Released: June, 2017
Urinary cytomegalovirus shedding
Released: January, 2016
Anti-Mullerian Hormone (AMH) & Inhibin-B
Released: January, 2015
Limited Access Data: Electrolytes – Urine
Released: September, 2012
Monoclonal gammopathy of undetermined significance (MGUS)
Released: August, 2012
Hepatitis C RNA (HCV-RNA) & HCV Genotype
Released: July, 2012
Epstein- Barr Virus (VCA-IgG)
Released: June, 2012
Fatty Acids – Plasma
Released: August, 2011
Autoantibodies – Immunofluorescence & Immunoprecipitation Analyses
Released: June, 2011
Sex Steroid Hormone – Men
Released: May, 2010
Melamine – Urine
Released: June, 2009
Varicella-Zoster Virus Antibody
Released: March, 2009
Mumps Antibody – Serum
Released: April, 2008
Cytomegalovirus IgG Antibodies – Serum
Released: March, 2008
Coxiella Burnetii (Q Fever) Antibodies – Serum
Released: February, 2008
Salmonella & Campylobacter Antibodies
Released: January, 2015
Volatile Organic Compounds & Metabolites
Released: February, 2014
Limited Access Data: Electrolytes – Urine
Released: September, 2012
Epstein-Barr Virus (VCA IgG) – Serum
Released: June, 2012
Klotho – Serum
Released: April, 2021
Hepatitis C Antibody Reflex Testing – Serum
Released: February, 2015
Epstein-Barr Virus (VCA IgG) – Serum
Released: June, 2012
Limited Access Data: Hemagglutination inhibition antibody titers to influenza A/ H1N1 viruses
Released: October, 2011
Urine specific gravity measurement
Released: April, 2011
Klotho – Serum
Released: April, 2021
Hepatitis C Antibody Reflex Testing – Serum
Released: February, 2015
Limited Access Data: Influenza A (H3N2) Variant Virus & Historical Seasonal H3N2 Influenza Viruses Antibodies
Released: January, 2015
Limited Access Data: Iodine – Urine – Pregnant Women
Released: January, 2015
Poliovirus Serotypes 1, 2, & 3 Antibodies – Serum
Released: August, 2014
Human Papillomavirus (HPV) viral Load Oral Rinse – Oral High Risk SPV Infections
Released: December, 2013
Limited Access Data: Human Papillomavirus (HPV) Viral Load – Oral Rinse – Oral High-Risk HPV Infections – Youth
Released: December, 2013
Limited Access Data: Avian Influenza A (H7N9) & Seasonal Influenza Viruses Antibodies
Released: November, 2013
Toxoplasma gondii antibody
Released: August,2013
Limited Access Data: Hemagglutination inhibition antibody titers to influenza A/ H1N1 viruses
Released: July, 2013
Limited Access Data: Sodium, Potassium & Chloride – Casual Urine
Released: September, 2012
Epstein-Barr Virus (VCA IgG) – Serum
Released: June, 2012
Autoantibodies – Anti-DFS70 Autoantibody Analyses
Released: July, 2022
Klotho – Serum
Released: April, 2021
Autoantibodies – Immunofluorescence Analyses
Released: August, 2019
Flame Retardants – Urine
Released: August, 2019
Antibody to Toxocara spp
Released: January, 2017
Toxoplasma Gondii Antibody – Serum
Released: January, 2016
Hepatitis C Antibody Reflex Testing – Serum
Released: February, 2015
Terpenes – Serum (Surplus)
Released: April, 2023
Glyphosate (GLYP) – Urine
Released: June, 2022
Serum Neurofilament Light Chain – Serum
Released: June, 2022
Klotho – Serum
Released: April, 2021
Limited Access Data: Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results – Youth
Released: November, 2020
Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results
Released: May, 2020
Perfluoroalkyl and Polyfluoroalkyl Substances
Released: April, 2019
Hepatitis C: Confirmed Antibody (INNO-LIA)
Released: January, 2018
Perfluroalkyl and Polyfluroalkyl Substances in U.S. Children 3-11 years
Released: August, 2017
Flame Retardant Metabolites
Released: July, 2017
Toxoplasma gondii antibody
Released: April, 2017
Antibody to Toxocara spp.
Released: January, 2017
Phthalates and Plasticizers Metabolizers (Urine)
Released: December, 2016
Limited Access Data: Electrolytes – MEC Urine Collection
Released: August, 2016
Perfluoroalkyl and Polyfluoroalkyl Substances – Linear and Branched PFOS and PFOA Isomers
Released: July, 2016
Chlorinated Tyrosine – Serum
Released: January, 2023
Glyphosate (GLYP) – Urine
Released: November, 2022
Flame Retardants – Urine
Released: July, 2022
Pertussis and tetanus – Serum
Released: June, 2022
Klotho – Serum
Released: April, 2021
Limited Access Data: Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results – Youth
Released: November, 2020
Chlamydia Pgp3 (plasmid gene product 3) ELISA (enzyme linked immunosorbent assay) and multiplex bead array (MBA) results
Released: May, 2020
DEET Metabolites – Urine – Surplus
Released: August, 2019
Neonicotinoids – Surplus Urine
Released: January, 2019
Mono-2-ethyl-5-hydroxyhexyl terephthalate, mono-2-ethyl-5-carboxypentyl terephthalate, and monooxoisononyl phthalate – Urine (Surplus)
Released: September, 2018
Limited Access Data: Hepatitis C: Confirmed Antibody (INNO-LIA) – 2015
Released: January, 2018
Flame Retardants – Urine (Surplus)
Released: February, 2023
Volatile Organic Compound (VOC) Metabolites II – Urine
Released: September, 2022
Perfluoroalkyl and Polyfluoroalkyl Substances (Surplus)
Released: December, 2020
Publications Using Serum, Plasma, and Urine Specimens
A list of publications using data resulting from collected Sera, Plasma, and Urine specimens.